Shenzhen presents $630m plan to increase AI, robotics - The Tamesis

Assistance consists of version qualifications, corpus qualifications and scenario-based aids to boost AI and robotics.

Post Views: 98

Tags

Related Posts

Can Japan PM Takaichi build a system to advance policy measures?: The Yomiuri Shimbun

January 21, 2026

Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.

January 20, 2026

Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.

January 19, 2026

The Tamesis

Leave a Reply Cancel reply

Latest from Blog

Indonesian President Prabowo’s nephew Thomas Djiwandono secures central bank deputy governor post

Australia pharma to reach $24.5b by 2030 despite ‘anniversary’ price cuts

Jonathan Cohen and Larroudé’s Partnership Is a Playbook for Modern Fashion Production

Inside ABC News Correspondent Will Reeve and Amanda Dubin’s Wedding at the Rubell Museum

Politics has become everyone’s game in Nepal

Limited imaging infrastructure drives MRI growth in India

Caretaker politics – Asia News NetworkAsia News Network

Gold To Keep Rising As Trust Flies Out The Window

Christie’s Koch Sale Signals Renewed Interest in American Art

Celebrated Gallerist Marian Goodman Dies at 97

Related Posts

Can Japan PM Takaichi build a system to advance policy measures?: The Yomiuri Shimbun

January 21, 2026

Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.

January 20, 2026

Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.

January 19, 2026

Don't Miss

Can Japan PM Takaichi build a system to advance policy measures?: The Yomiuri Shimbun

January 21, 2026 Tokyo – “I

Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.

Singapore’s biopharmaceutical industry is expected to